MyEClinic
MyEClinic
Health Dictionary Find a Doctor

Casopitant

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Casopitant (trade names Rezonic (US), Zunrisa (EU)) is an neurokinin 1 (NK1) receptor antagonist undergoing research for the treatment of chemotherapy-induced nausea and vomiting (CINV).[1] It is currently under development by GlaxoSmithKline (GSK).

In July 2008, the company filed a marketing authorisation application with the European Medicines Agency. The application was withdrawn in September 2009 because GSK decided that further safety assessment was necessary.[2]

See also


References

  1. ↑ Lohr L (2008). “Chemotherapy-induced nausea and vomiting”. Cancer J. 14 (2): 85–93. doi:10.1097/PPO.0b013e31816a0f07. PMID 18391612.
  2. ↑ “GlaxoSmithKline withdraws its marketing authorisation application for Zunrisa” (PDF). London: EMEA. 13 October 2009. Retrieved 21 December 2009.

Template:Antiemetics and antinauseants Template:Antidepressants Template:Anxiolytics

Imprint

Privacy Policy

Terms and Conditions

© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH